Syndax Pharmaceuticals (SNDX) Share-based Compensation (2015 - 2026)

Syndax Pharmaceuticals' Share-based Compensation history runs 12 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 16.12% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $49.2 million (up 10.49% YoY), while the FY2025 annual figure was $78.7 million, down 3.55% from the prior year.
• Share-based Compensation for Q1 2026 stood at $12.1 million, up from $11.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $13.8 million in Q2 2025, with the low at $346000.0 in Q3 2022.
• The 5-year median for Share-based Compensation is $8.9 million (2024), against an average of $8.6 million.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation tumbled 89.77% in 2022, then soared 2304.91% in 2023.
• Syndax Pharmaceuticals' Share-based Compensation stood at $4.2 million in 2022, then soared by 96.35% to $8.3 million in 2023, then soared by 47.68% to $12.3 million in 2024, then slipped by 8.48% to $11.3 million in 2025, then increased by 7.1% to $12.1 million in 2026.
• Business Quant data shows SNDX's Share-based Compensation at $12.1 million in Q1 2026, $11.3 million in Q4 2025, and $12.1 million in Q3 2025.